Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy

Qian, Cheng; Liu, Chaoqun; Liu, Weiwei; Zhou, Rui; Zhao, Liang

doi:10.3389/fimmu.2023.1291530

Cited by 7 publications

(1 citation statement)

References 217 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been observed that lenvatinib inhibits the angiogenic factor in the tumor microenvironment and blocks fibroblast growth factor receptor 4 (FGFR4). This reduces tumor PD–L1 expression and impedes the differentiation of regulatory T cells (Tregs), thereby improving the efficacy of PD–1 antibodies ( 28 , 29 ). The combination of TKIs and PD–1 antibodies presents a favorable therapeutic option for eliminating microsatellite foci that have not yet been detected by imaging ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma

Men,

Cui,

Han

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with microwave ablation (MWA) adjuvant to lenvatinib and anti–PD–1 antibodies for patients with hepatocellular carcinoma (HCC).MethodsA retrospective analysis of 67 patients with HCC treated at our hospital between October 2018 and May 2022 was conducted. All patients underwent a combination of TACE and MWA. Among them, 29 received postoperative treatment with molecular–targeted agents, like lenvatinib, along with anti–PD–1 antibodies such as sindilizumab, karelizumab, or tirilizumab. The remaining 38 patients did not receive postoperative systemic therapies, like targeted or immunotherapy. The survival and prognosis of all patients were analyzed.ResultsNine patients in the observation group and 29 patients in the control group experienced recurrence, and the median progression–free survival 1 (PFS1) was not reached ‘Not Applicable’(NA) and 17.05 months (P=0.035), respectively. Failure to combine adjuvant therapy was identified as an independent risk factor for tumor recurrence, and the observation group had a 0.245 times lower risk of recurrence compared to that in the control group (P=0.005). Multivariable Cox regression analysis confirmed that the maximum tumor size, and tumor number were risk factors for tumor recurrence. Patients with a large maximum tumor size had a 1.519 times higher risk of recurrence compared to those with a small maximum tumor size (P=0.006), and patients with a large number of tumors had a 5.978 times higher risk of recurrence compared to those with a small number of tumors (P=0.02). The median PFS2 of the two groups was 11.795 and 21.257 months, respectively, though not statistically significant (P=0.955). However, there was a disparity in the percentage of BCLC stages associated with recurrence between the two groups. In the observation group approximately 22.22% of patients progressed to stage C, while in the control group, this proportion was 34.48%. The observation group exhibited a lower risk of distant metastasis compared to the control group.ConclusionAdjuvant treatment of HCC following TACE combined with MWA improved PFS and achieved better clinical outcomes compared to that with TACE combined with MWA alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma

Men,

Cui,

Han

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

The influence of endothelial metabolic reprogramming on the tumor microenvironment

Kane,

Edwards,

Chen

2024

Oncogene

View full text Add to dashboard Cite

Endothelial cells (ECs) that line blood vessels act as gatekeepers and shape the metabolic environment of every organ system. In normal conditions, endothelial cells are relatively quiescent with organ-specific expression signatures and metabolic profiles. In cancer, ECs are metabolically reprogrammed to promote the formation of new blood vessels to fuel tumor growth and metastasis. In addition to EC’s role on tumor cells, the tortuous tumor vasculature contributes to an immunosuppressive environment by limiting T lymphocyte infiltration and activity while also promoting the recruitment of other accessory pro-angiogenic immune cells. These elements aid in the metastatic spreading of cancer cells and contribute to therapeutic resistance. The concept of restoring a more stabilized vasculature in concert with cancer immunotherapy is emerging as a potential approach to overcoming barriers in cancer treatment. This review summarizes the metabolism of endothelial cells, their regulation of nutrient uptake and delivery, and their impact in shaping the tumor microenvironment and anti-tumor immunity. We highlight new therapeutic approaches that target the tumor vasculature and harness the immune response. Appreciating the integration of metabolic state and nutrient levels and the crosstalk among immune cells, tumor cells, and ECs in the TME may provide new avenues for therapeutic intervention.

show abstract

The Past and Future of Angiogenesis as a Target for Cancer Therapy and Prevention

Albini,

Noonan,

Corradino

et al. 2024

Cancer Prevention Research

View full text Add to dashboard Cite

Cancer growth is dependent on angiogenesis, the formation of new blood vessels, which represents a hallmark of cancer. Since this concept was established in the Seventies, inhibition of tumor development and metastases by blocking the neoangiogenic process has been an important approach to the treatment of tumors. However, antiangiogenic therapies are often administered when cancer has already progressed. The key to reducing the cancer burden is prevention. We noticed 20 years ago that a series of possible cancer chemopreventive agents showed antiangiogenic properties when tested in experimental models. This article reviews the relevant advances in the understanding of the rationale for targeting angiogenesis for cancer therapy and prevention and on substances with antiangiogenic activity that may be suitable for such strategies. Many compounds, either dietary derivatives or repurposed drugs, with antiangiogenic activity are possible tools for cancer angioprevention. Such molecules have a favorable safety profile and are likely to allow the prolonged duration necessary for an efficient preventive strategy. Recent evidence on mechanisms and possible use is described here for food derivatives, including flavonoids, retinoids, triterpenoids, omega fatty acids, and carotenoids from marine microorganisms. As examples, a number of compounds, including epigallocatechin, resveratrol, xanthohumol, hydroxytyrosol, curcumin, fenretinide, lycopene, fucoxanthin, and repurposed drugs, such as aspirin, β-blockers, renin–angiotensin–aldosterone inhibitors, carnitines, and biguanides are reviewed.

show abstract

Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy

Cited by 7 publications

References 217 publications

Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma

Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma

The influence of endothelial metabolic reprogramming on the tumor microenvironment

The Past and Future of Angiogenesis as a Target for Cancer Therapy and Prevention

Contact Info

Product

Resources

About